If you go to the Abbvie site and click on Humira, they summarize it like they do on the commercial. I'm shocked its a 7.4B dollar drug with that #$%$ safety profile. The patent expires in 2016 though. We should be able to steal some of those revs, especially if we can expand into Crohn's and the other Humira indications.
Our safety profile is better than anything on the market, so far.
LOL - John Deere sounds good, but rt got it.....Dose Escalation. They are dosing at 0.6 mg/kg which is 2x the previous high dose.
BB bought LJPC @ 0.07
I spoke to their CEO (Tidmarsh). Seems like an okay guy, but with 200M+ float and SP less than 0.15, I fear R/S is imminent. They already obtained shareholder approval too. It's something to keep an eye on though. GALT is in the same arena. I'd keep an eye on them as well.
IDRA still #1 though.
We'll have to do a much larger P3 in the states, but IDRA was smart to do P1 with IMO-3100, modify formula to create IMO-8400 then DE in P2b. This saves shareholders money while proving proof of concept, method of action and stat sig. They'll have all the data they need to run a successful P3. The study length is only 12 weeks so getting IMO-8400 to market in 2015 should be no problem. I'm not sure if Agrawal was referring to fast track on the psoriasis study, waldstruems or another indication with IMO-9200. When I like at Humira, I see how 1 drug is used for so many indications and brings in 7B in revs/yr. It's possible IDRA can have 1 or more drugs for numerous indications. The speed and financial efficiency they are running these trials at is an added bonus. Good times ahead my friend!
Thanks for looking into it. It sounds like something Cramer or his minion AF would say. But, thanks to you at least we know. Thanks again!
I'm torn between the general behavior of bios and what we have going on here. Generally, bios won't breach a 300M MC prior to P2 results. However, this general rule has been broken many times this year with MACK being the most recent. Stocks like this go into a special category of which IDRA has become. With the amount of accumulation going on, there's more to this story and I can't wait to see it unfold. Today is a classic example of why IDRA is not a stock to trade, but a stock to buy, hold and accumulate.
I've never bought one, but I'd have to imagine the more expensive one would be better....the salesmen see me coming from a mile away. I'm just drawn to the higher price tags!
Very similar companies that will be sharing the same space. IDRA just getting their feet wet, so the growth will be exponential like PCYC.
PCYC is looking great at these prices too. I'm actually surprised it crossed the 200 dma.
Hey there wake, of all the companies I've looked at, I only feel safe investing in IDRA for multi-bagger gains with the greatest chance of success in the shortest amount of time with the least amount of risk. I'm having a little bit of a hard time adjusting from a trader to investor (especially on days like today), but so far so good. I'm not sure if I'm going to have the time to write a thorough SA article, but I will surely at least post a lot of good stuff in the coming days. The things I post will reinforce why IDRA is the stock that transitioned me from trader to investor.
As I've previously mentioned, the dose escalation portion of the IMO-8400 P2 completed enrollment in September. I'm unaware of the exact date, but it is possible that the study has finalized with the last pt completing the 12 weeks. Since there are only 44 pts in the study (32 + 12DE), a 1st glance of data can be rather telling. Looking at data routinely in my day job, I make "off the cuff" analyses on a first glance and can get a very good indication of pass, fail or too close to call. It's just a guess, but the timing is in the ballpark.